All In Biotech

Drug Trial Radar · NCT07035990

Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SION-451 and Complementary Modulators SION-2222 and SION-109 in Healthy Participants.

A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of SION-451, and Multiple Dose Combinations of SION-451 and Complementary Modulators SION-2222 and SION-109 in Healthy Participants.

Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

Jul 23, 2025

Primary completion

Mar 23, 2026

Study completion Mar 23, 2026

Sponsor

Lead sponsor
Sionna Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Jun 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of Parts D and E of this Phase 1 study are to evaluate the safety, tolerability, and pharmacokinetics of multiple dose combinations of SION-451 and complementary modulators SION-2222 and SION-109 in healthy participants.

Conditions

  • Cystic Fibrosis (CF)

Interventions

  • SION-451Drug

    * Pharmaceutical form: tablet * Route of administration: oral

  • SION-2222Drug

    * Pharmaceutical form: capsule * Route of administration: oral

  • SION-109Drug

    * Pharmaceutical form: tablet * Route of administration: oral

  • Placebo SION-451Drug

    Placebo matched to SION-451

  • Placebo SION-2222Drug

    Placebo matched to SION-2222

  • Placebo SION-109Drug

    Placebo matched to SION-109

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the incidence of treatment emergent adverse events [Safety and Tolerability] of SION-451 and SION-109 when administered in combination to healthy participantsTime frame: From Day 1 through day 21
  2. To evaluate the incidence of treatment emergent adverse events [Safety and Tolerability] of SION-451 and SION-2222 when administered in combination to healthy participantsTime frame: From Day 1 through day 21

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network

    Brisbane, Queensland, Australia

  • Nucleus Network

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.